The proteinaceous biofilm of Gardnerella vaginalis enables a novel enzymatic therapy for bacterial vaginosis

阴道加德纳菌的蛋白质生物膜为细菌性阴道炎的新型酶疗法提供了可能。

阅读:2

Abstract

Since it was first reported in the 1950s, bacterial vaginosis (BV) has become a globally vital concern among women of childbearing age. Gardnerella vaginalis is widely recognized as the primary causative agent responsible for BV development. G. vaginalis has a strong tendency to form biofilms which have been linked to widespread antimicrobial tolerance and recurrent or persistent BV episodes. Our study demonstrated that proteins constitute more than 50% of the G. vaginalis biofilm matrix, which significantly protects the bacterium from degradation by lysozyme, and that LasA, an elastase derived from Pseudomonas aeruginosa, effectively disrupts G. vaginalis biofilms and subsequently lyses the bacterial cell wall, leading to cell death. Four candidate biofilm-associated proteins of G. vaginalis were identified using cross-linking mass spectrometry (XL-MS) and subsequently confirmed as LasA substrates through purification and LasA digestion. Peptidoglycan debris was observed after treating the G. vaginalis cell wall extract with LasA. We also found that LasA showed a minimal adverse effect on lactobacilli strains when used in vitro. In vivo studies utilizing murine models artificially infected with G. vaginalis further demonstrated that a single dose of LasA effectively reduces G. vaginalis colonization while exerting a negligible adverse effect on lactobacilli populations. The safety of LasA was further supported by the fact that no negative effects were observed on the treated mice's vaginal tissue sections during the post-treatment administration period.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。